2 completed, 2 terminated. 4 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Terminated 2 |
| Phase 1 | 1 | Completed 1 |
Follow ICON Bioscience Inc: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of IBI-10090 in Ocular Surgery Patients IBI-10090 - Inflammation Associated With Cataract Surgery | Phase 2 | Completed | ICON Bioscience Inc | 172 | 2012-04-01 | 2014-09-22 |
| Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients IBI-10090 - Ocular Inflammation | Phase 2 | Terminated | ICON Bioscience Inc | 42 | 2010-10-01 | 2013-09-18 |
| 20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD) IBI-20089/Lucentis - Age-Related Macular Degeneration, Choroidal Neovascularization | Phase 1 / Phase 2 | Completed | University of Illinois at Chicago | 10 | 2010-09-01 | 2014-10-20 |
| Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery IBI-10090 - Inflammatory Reaction Due to Ocular Lens Prosthesis | Phase 2 | Terminated | ICON Bioscience Inc | 6 | 2010-01-01 | 2018-12-04 |
Cataract (1) · Choroidal Neovascularization (1) · Inflammation (1) · Macular Degeneration (1)
Ranibizumab (1) · Triamcinolone Acetonide (1)
United States (4)
David Chang, MD (1) · Jennifer I Lim, MD (1) · Mark Packer, MD (1) · Wendy Murahashi, MD (1)